TATDN1

Across TCGA pan-cancer cohorts, TATDN1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TATDN1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TATDN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TATDN1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where TATDN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.618	0.787	.031	5	view →
PDAC	OS	Median	II,III,IV	0.962	0.703	.014	4	view →
LUAD	OS	Median	III,IV	0.897	0.333	.013	4	view →
LSCC	DFS	Median	All	0.464	0.907	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TATDN1–CCRCC (DFS)

Open the CCRCC breakdown →